This is a medicine used to help manage diabetes. It works by helping your kidneys remove extra sugar from your urine, which helps lower your blood sugar levels. It's often taken as a pill.
Every report comes from a Lived member, sent anonymously.
Have you tried Invokana (Canagliflozin) for Type 2 Diabetes?
Canagliflozin, sold under the brand name Invokana, is a prescription tablet for type 2 diabetes. It belongs to a group of medicines called SGLT2 (sodium-glucose co-transporter 2) inhibitors, which lower blood sugar by helping the kidneys clear extra sugar into the urine. Along with diet and exercise, it is approved to improve blood sugar control in adults and in children 10 years and older. In adults with type 2 diabetes, it has two further approved uses that go beyond blood sugar. For people who already have heart or blood vessel disease, it lowers the risk of heart attack, stroke and death from cardiovascular causes. For people whose diabetes has damaged their kidneys and who lose a large amount of protein in their urine (more than 300 mg a day), it lowers the risk of kidney failure, a serious decline in kidney function, death from heart causes and hospital stays for heart failure. These protective effects are a main reason it may be chosen over medicines that only lower blood sugar. Canagliflozin is also sold combined with metformin as Invokamet and Invokamet XR, which carry metformin's own cautions as well. It is not used for blood sugar control in type 1 diabetes, where it markedly raises the risk of a dangerous condition called ketoacidosis.
The kidneys filter sugar out of the blood and then reabsorb nearly all of it, so normally little ends up in the urine. A protein called SGLT2 does most of that reabsorbing. Canagliflozin blocks this protein, so more sugar leaves the body in the urine and blood sugar falls. The sugar draws water and some sodium out with it. That explains the extra urination, and the modest drops in blood pressure and body weight that many people see. Blocking SGLT2 also changes how much sodium reaches deeper parts of the kidney, which is believed to lower the pressure inside the kidney's tiny filters. This is one proposed reason the medicine helps protect the kidneys over time.
Canagliflozin is a tablet taken by mouth once a day, before the first meal of the day. Most people start at 100 mg. For blood sugar control, the prescriber may raise it to 300 mg if the lower dose is well tolerated, more control is needed and kidney function is good enough. For heart and kidney protection, the dose is 100 mg. Kidney function is checked with a blood test before starting and from time to time afterward. The result is reported as eGFR (estimated glomerular filtration rate), a measure of how well the kidneys filter blood; lower numbers mean the kidneys are filtering less. When eGFR is between 30 and 60, the dose stays at 100 mg, and starting the medicine is not recommended when eGFR is below 30. Some adults already taking it for kidney protection may continue at lower levels, a decision made with the prescriber. Dehydration should be corrected before the first dose. If possible, canagliflozin is stopped at least 3 days before surgery or a procedure that requires a long period without food, and restarted once the person is stable and eating and drinking again. If a dose is missed, take it as soon as remembered, but do not double up the next dose.
The most common side effects follow from the sugar in the urine. Genital yeast infections are among the most frequent, in both women and men, and urinary tract infections and more frequent urination are also common. Some people notice thirst or a dry mouth. People who have had these infections before are more likely to get them again, and they are worth reporting so they can be treated rather than endured. Because the medicine removes fluid, it can lower blood pressure enough to cause dizziness or lightheadedness, especially on standing. This is more likely in older adults, people with reduced kidney function and people taking strong diuretics (water pills). Drinking enough fluid helps, and dizziness should be mentioned to the prescriber. Significant fluid loss can also lead to sudden kidney injury. A rare but serious risk is ketoacidosis, a buildup of acids called ketones in the blood. With canagliflozin it can happen even when blood sugar is normal or only mildly raised, so a normal glucose reading does not rule it out. It is more likely during an illness with fever, when eating very little or following a ketogenic diet, around surgery, with dehydration or heavy alcohol use, when insulin doses are missed or reduced, and in people with a history of pancreatitis or pancreatic surgery. Nausea, vomiting, stomach pain, unusual tiredness or labored breathing are reasons to stop the medicine and get medical care right away. Some people are asked to check ketones at home. Rarely, a severe infection of the skin and deeper tissue between the genitals and the anus (Fournier's gangrene) has occurred. Pain, tenderness, redness or swelling in that area along with a fever above 100.4°F or feeling generally unwell needs prompt medical attention the same day. Serious allergic reactions are also rare and usually appear within hours to days of starting. Swelling of the face, lips, tongue or throat needs emergency care; hives or a new rash should be reported promptly, with the medicine paused until the prescriber has been consulted.
Canagliflozin has been linked to a higher risk of amputation, most often of the toes or middle of the foot and less often of the leg. In two large trials of people with type 2 diabetes and heart disease or high heart risk, amputations occurred at roughly twice the rate seen with placebo (about 6 versus 3 per 1,000 people each year); in a later trial of people with diabetic kidney disease, the difference was much smaller. Most amputations followed a foot infection, ulcer or gangrene. The risk is highest in people who have had an amputation before, have poor circulation in the legs (peripheral vascular disease) or have nerve damage in the feet (neuropathy). Routine foot care and daily checks matter, and any new pain, tenderness, sore, ulcer or infection of the foot or leg should be reported to the care team right away. Taken with insulin or a sulfonylurea (an older type of diabetes pill that prompts the pancreas to release insulin), canagliflozin raises the risk of low blood sugar, so the dose of those medicines may be lowered. Anyone on that combination should know the signs of low blood sugar and how to treat it. Canagliflozin also raises levels of digoxin, a heart medicine, and can lower levels of lithium, a mood stabilizer, so both may need closer monitoring. Some medicines, including the antibiotic rifampin, the seizure medicines phenytoin and phenobarbital, and the HIV medicine ritonavir, weaken its effect and may call for a higher dose. An increased risk of bone fractures, appearing as early as 12 weeks after starting, was seen in one large trial, so people already at risk of fractures should weigh this with their prescriber. Canagliflozin is not recommended in the second and third trimesters of pregnancy or while breastfeeding, because animal studies showed harm to the developing kidney. Poorly controlled diabetes also carries risks in pregnancy, so anyone pregnant or planning pregnancy should talk with the prescriber early about the best treatment. People who have had a serious allergic reaction to canagliflozin should not take it again.
More frequent urination often starts soon after the first doses. Blood sugar control is judged mainly by the A1C (hemoglobin A1C) blood test, which reflects average blood sugar over the past three months, so the full effect of a dose is assessed over months rather than days. While taking canagliflozin, urine glucose tests will always read positive and cannot be used to track diabetes; blood glucose readings and A1C are used instead. For people taking it to protect the heart or kidneys, the benefit is a lower chance of serious events over years, not something felt day to day. In the main kidney trial, the combined risk of kidney failure, doubling of a key kidney blood test, and death from kidney or heart causes was about 30% lower than with placebo over about two and a half years. Ongoing care usually includes periodic kidney function tests, blood pressure checks and attention to the feet. Because illness, fasting and surgery raise the risk of ketoacidosis and dehydration, it helps to agree on a sick-day plan in advance, including when to pause the medicine and when to restart it.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Invokana (Canagliflozin), what you've noticed, or ask the community a question.